FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See	Instruction 10.			
1. Name and Address of Reporting Person * Goin Kathleen			2. Issuer Name and Ticker or Trading Symbol PALVELLA THERAPEUTICS, INC. [PVLA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
I		` ,	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2025	X Officer (give title Other (specify below) Chief Operating Officer
125 STRAFFORD AVENUE, SUITE 360			4. If Amendment, Date of Original Filed (Month/Day/Year) 02/07/2025	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
(Street) WAYNE	PA	19087		Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Incentive Stock Option (right to buy)	\$14.76	02/05/2025		A		5,373		(1)	02/05/2035	Common Stock	5,373	\$0.0	5,373	D	
Non-Qualified Stock Option (right to buy)	\$14.76	02/05/2025		A		123,559		(1)	02/05/2035	Common Stock	123,559	\$0.0	123,559	D	

Explanation of Responses:

1. The stock options will vest in equal monthly tranches over 48 months

Remarks:

This amendment is being filed to reflect a change in the reporting person's name from Palvella Therapeutics, Inc to Kathleen Goin.

By: /s/ Kathleen A. McGowan
For: Kathleen Goin

02/10/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.